PSMA PET Prep Product Gozellix Garners FDA Approval
Indicated for use in cases involving suspected metastasis with PCa or suspected PCa recurrence due to elevated PSA level, Gozellix reportedly has a longer shelf life than other gallium-based PET imaging products.
The Food and Drug Administration (FDA) has approved Gozellix® (TLX007-CDx), a new preparation kit for the PSMA PET agent gallium-68 (68Ga) gozetotide.
After radiolabeling with 68Ga, Gozellix is indicated for PSMA PET imaging of men with suspected metastasis of prostate cancer (PCa), according to Telix Pharmaceuticals, the developer of Gozellix. The company said Gozellix is also approved for PSMA PET imaging in cases of suspected PCa recurrence based on elevated prostate-specific antigen (PSA) level.
For men with suspected metastasis or recurrence of prostate cancer, the FDA has approved the use of Gozellix, a preparation kit for the PSMA PET agent 68Ga gozetotide, which offers a longer shelf life (up to six hours) than other gallium-based PSMA PET products, according to Telix Pharmaceuticals, the developer of Gozellix. (Image courtesy of Adobe Stock.)
Telix Pharmaceuticals noted that key advantages with Gozellix include a longer shelf life (up to six hours) in comparison to other gallium-based PSMA PET products. An extended distribution radius may enable the use of Gozellix in PET scanning for areas not being served by other PSMA imaging providers, according to the company.
(Editor’s note: For additional content on prostate cancer imaging, click here.)
Emphasizing the scalable production capability with Gozellix, Telix Pharmaceuticals suggested the product facilitates flexibility with scheduling and efficiency of PSMA PET scanning, bolstering access to the imaging technology for patients with prostate cancer.
“Securing FDA approval for Gozellix is a major win for prostate cancer patients, who gain enhanced access to state-of-the-art 68Ga PSMA-PET imaging,” noted Kevin Richardson, the chief executive officer for Telix Precision Medicine. “With the launch of Gozellix, our team is excited to be bringing the new generation of prostate cancer scanning to more American men, delivered with the reliability, service and flexibility that customers have come to expect from Telix.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
